Fecal Incontinence (FI) is a condition in which individuals lose control of bowel movements leading to unexpected, involuntary leakage of stools. As per DelveInsight, Fecal Incontinence prevalence was observed to be 11,345,694 in 2020 in the 7MM. Similarly, the Fecal Incontinence Therapeutics Market Size was estimated to be USD 1880 million in 2020 in the 7MM, which is further expected to grow by 2030.
Currently, some of the prominent companies developing novel and effective therapies to expand the Fecal Incontinence Therapeutics Market includes Cook MyoSite, 9 Meters Biopharma, Palette Life Sciences, and others. The Fecal Incontinence Market is expected to rise at a CAGR of 3.96% during the study period (2018-30) in the 7MM (i.e. the US, EU5, and Japan) owing to the key factors such as the increase in prevalence, rise in the R&D activity, and an increase in the awareness around the condition. Some of the pipeline therapies in the Fecal Incontinence Therapeutics Market are in various phases of clinical development expected to launch in the coming years and provide a new dimension to the therapeutic market.
For more details, visit: Fecal Incontinence Therapy Market